57 related articles for article (PubMed ID: 25190507)
21. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Shi W; Fu Y; Wang Y
Oncol Lett; 2021 Jul; 22(1):527. PubMed ID: 34055092
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.
Chung S; Tamura K; Furihata M; Uemura M; Daigo Y; Nasu Y; Miki T; Shuin T; Fujioka T; Nakamura Y; Nakagawa H
Cancer Sci; 2009 Nov; 100(11):2109-14. PubMed ID: 19664042
[TBL] [Abstract][Full Text] [Related]
24. Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Res Commun; 2022 Oct; 626():51-57. PubMed ID: 35970044
[TBL] [Abstract][Full Text] [Related]
25. NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Hou SQ; Liu L
Front Biosci (Landmark Ed); 2015 Jun; 20(7):1179-89. PubMed ID: 25961552
[TBL] [Abstract][Full Text] [Related]
26. Aberrant STYK1 expression in ovarian cancer tissues and cell lines.
Jackson KA; Oprea G; Handy J; Kimbro KS
J Ovarian Res; 2009 Oct; 2(1):15. PubMed ID: 19845955
[TBL] [Abstract][Full Text] [Related]
27. The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Rep; 2024 Jul; 38():101709. PubMed ID: 38638675
[TBL] [Abstract][Full Text] [Related]
28. Insights into molecular pathways for targeted therapeutics in acute leukemia.
Stavropoulou V; Brault L; Schwaller J
Swiss Med Wkly; 2010; 140():w13068. PubMed ID: 20853191
[TBL] [Abstract][Full Text] [Related]
29. RBM15 condensates modulate m
Jiang A; Zhang S; Wang X; Li D
Comput Struct Biotechnol J; 2022; 20():4825-4836. PubMed ID: 36147665
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of retinoic acid-induced transcription: histone code, DNA oxidation and formation of chromatin loops.
Zuchegna C; Aceto F; Bertoni A; Romano A; Perillo B; Laccetti P; Gottesman ME; Avvedimento EV; Porcellini A
Nucleic Acids Res; 2014; 42(17):11040-55. PubMed ID: 25217584
[TBL] [Abstract][Full Text] [Related]
31. Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma.
Hua HW; Jiang F; Huang Q; Liao ZJ; Ding G
Tumour Biol; 2015 Jan; 36(1):303-13. PubMed ID: 25252848
[TBL] [Abstract][Full Text] [Related]
32. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
Mata M; Vera JF; Gerken C; Rooney CM; Miller T; Pfent C; Wang LL; Wilson-Robles HM; Gottschalk S
J Immunother; 2014 Oct; 37(8):407-15. PubMed ID: 25198528
[TBL] [Abstract][Full Text] [Related]
33. The new advance of SALL4 in cancer: Function, regulation, and implication.
Abouelnazar FA; Zhang X; Wang M; Zhang J; Yu D; Zang X; Zhang J; Li Y; Xu J; Yang Q; Zhou Y; Tang H; Wang Y; Gu J; Zhang X
J Clin Lab Anal; 2023 May; 37(9-10):e24927. PubMed ID: 37337914
[TBL] [Abstract][Full Text] [Related]
34. STYK1/NOK affects cell cycle late mitosis and directly interacts with anaphase-promoting complex activator CDH1.
Zeng SL; Patel SS; Lv MQ; Zhu D; Shen WH; Liu L
Heliyon; 2022 Dec; 8(12):e12058. PubMed ID: 36506394
[TBL] [Abstract][Full Text] [Related]
35. Low STYK1 expression indicates poor prognosis in gastric cancer.
Fang J; Wang H; Fang X; Li N; Hu H; Bian M; Yang P
Cancer Manag Res; 2018; 10():6669-6676. PubMed ID: 30584361
[TBL] [Abstract][Full Text] [Related]
36. Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.
Chen L; Ma C; Bian Y; Shao C; Wang T; Li J; Chong X; Su L; Lu J
Oncotarget; 2017 Dec; 8(67):111333-111345. PubMed ID: 29340057
[TBL] [Abstract][Full Text] [Related]
37. Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.
Hu L; Chen HY; Cai J; Zhang Y; Qi CY; Gong H; Zhai YX; Fu H; Yang GZ; Gao CF
BMC Cancer; 2015 Apr; 15():246. PubMed ID: 25884558
[TBL] [Abstract][Full Text] [Related]
38. Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
Nirasawa S; Kobayashi D; Kondoh T; Kuribayashi K; Tanaka M; Yanagihara N; Watanabe N
Int J Oncol; 2014 Nov; 45(5):1867-74. PubMed ID: 25190507
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T; Kobayashi D; Tsuji N; Kuribayashi K; Watanabe N
Exp Hematol; 2009 Jul; 37(7):824-30. PubMed ID: 19409952
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
